Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vose

Showing results (571-580 of 891) with videos related to

Pageof 90
Sort By:
British Journal of Haematology|June 29, 2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological originMyron S Czuczman, Julie M Vose, Thomas E Witzig, et al.
Infection Control and Hospital Epidemiology|March 1, 1993
Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplantsP C Iwen, E C Reed, J O Armitage, et al.
Blood|October 15, 1992
Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-upJ M Vose, P J Bierman, J R Anderson, et al.
Leukemia & Lymphoma|September 17, 2004
Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study GroupJames Z Huang, Dennis D Weisenburger, Julie M Vose, et al.
The American Journal of Medicine|September 1, 1989
Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantationJ M Vose, J O Armitage, P J Bierman, et al.
Experimental Hematology|December 1, 1995
Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxisS Martin-Algarra, M R Bishop, S Tarantolo, et al.
Annals of Hematology|October 20, 2021
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphomaMridula Krishnan, R Gregory Bociek, Michelle Fanale, et al.
The Science of the Total Environment|April 20, 2023
Forested watersheds provide the highest water quality among all land cover types, but the benefit of this ecosystem service depends on landscape contextPeter V Caldwell, Katherine L Martin, James M Vose, et al.
Thrombosis and Haemostasis|March 22, 2024
Endothelial LAT1 (SLC7A5) Mediates S-Nitrosothiol Import and Modulates Respiratory Sequelae of Red Blood Cell Transfusion In VivoHongmei Zhu, Richard L Auten, Augustus Richard Whorton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's diseaseP J Bierman, J M Vose, P K Leichner, et al.
Pageof 90

Showing results (571-580 of 891) with videos related to

Sort By:
Pageof 90
British Journal of Haematology|June 29, 2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological originMyron S Czuczman, Julie M Vose, Thomas E Witzig, et al.
Infection Control and Hospital Epidemiology|March 1, 1993
Nosocomial invasive aspergillosis in lymphoma patients treated with bone marrow or peripheral stem cell transplantsP C Iwen, E C Reed, J O Armitage, et al.
Blood|October 15, 1992
Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-upJ M Vose, P J Bierman, J R Anderson, et al.
Leukemia & Lymphoma|September 17, 2004
Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: a report of 21 cases from the Nebraska Lymphoma Study GroupJames Z Huang, Dennis D Weisenburger, Julie M Vose, et al.
The American Journal of Medicine|September 1, 1989
Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing autologous bone marrow transplantationJ M Vose, J O Armitage, P J Bierman, et al.
Experimental Hematology|December 1, 1995
Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxisS Martin-Algarra, M R Bishop, S Tarantolo, et al.
Annals of Hematology|October 20, 2021
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphomaMridula Krishnan, R Gregory Bociek, Michelle Fanale, et al.
The Science of the Total Environment|April 20, 2023
Forested watersheds provide the highest water quality among all land cover types, but the benefit of this ecosystem service depends on landscape contextPeter V Caldwell, Katherine L Martin, James M Vose, et al.
Thrombosis and Haemostasis|March 22, 2024
Endothelial LAT1 (SLC7A5) Mediates S-Nitrosothiol Import and Modulates Respiratory Sequelae of Red Blood Cell Transfusion In VivoHongmei Zhu, Richard L Auten, Augustus Richard Whorton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's diseaseP J Bierman, J M Vose, P K Leichner, et al.
Pageof 90